替罗非班应用于急性颅内非大血管闭塞性进展性脑梗死患者的疗效及安全性

Therapeutic effect of tirofiban on patients with acute non-intracranial large vessel occlusive progressive cerebral infarction and its safety

目的:研究替罗非班应用于颅内非大血管闭塞性进展性脑梗死患者的疗效及安全性。方法:根据是否应用替罗非班,于我科治疗的93例急性颅内非大血管闭塞性进展性脑梗死患者被分为常规治疗组(47例)与替罗非班组(46例,在常规治疗组基础上接受替罗非班)。观察比较两组治疗前及治疗72h后美国国立卫生研究院卒中量表(NIHSS)评分、治疗3个月后改良Rankin量表(MRS)评分及出血并发症发生率。结果:与常规治疗组比较,治疗72h后替罗非班组NIHSS评分降低更显著[3.00(2.00,7.00)分比3.00(2.00,5.25)分,P=0.044],治疗3个月后替罗非班组MRS评分降低更显著[2.00(1.00,4.00)分比1.00(0.00,2.00)分,P=0.010]。两组出血并发症发生率无显著差异(P=0.985)。结论:替罗非班能显著改善颅内非大血管闭塞性进展性脑梗死患者临床症状及预后,且安全性好。

Objective:To study therapeutic effect of tirofiban on patients with acute non-intracranial large vessel occlusive progressive cerebral infarction and its safety.Methods:According to tirofiban applied or not,a total of 93 patients with acute non-intracranial large vessel occlusive progressive cerebral infarction treated in our department were divided into routine treatment group(n=47)and tirofiban group(n=46,received tirofiban based on routine treatment group).National institutes of health stroke scale(NIHSS)score before and 72h after treatment,score of modified Rankin scale(MRS)three months after treatment and incidence rate of bleeding complications were observed and compared between two groups.Results:Compared with routine treatment group,there were significant reduction in NIHSS score[3.00(2.00,7.00)scores vs.3.00(2.00,5.25)scores,P=0.044]72h after treatment and MRS score[2.00(1.00,4.00)scores vs.1.00(0.00,2.00)scores,P=0.010]three months after treatment in tirofiban group.There was no significant difference in incidence rate of bleeding complications between two groups(P=0.985).Conclusion:Tirofiban can significantly improve clinical symptoms and prognosis in patients with acute non-intracranial large vessel occlusive progressive cerebral infarction with good safety.